A cluster of Bay State biotech heavy hitters, including Moderna, Praxis Precision Medicines and Southborough-based Milestone Heights, has signed onto a new national trade group aimed at shoring up U.S. biotech as Chinese rivals scale up fast. The American Biotech Innovation Alliance pulls together emerging and midsize firms that say they want a sharper national strategy on manufacturing, talent and regulatory policy. Local leaders are pitching the move as a way to keep development, production and high-value jobs rooted in Massachusetts rather than drifting overseas.
The group officially launched on May 5 with 21 founding members, according to BusinessWire. "We've spent decades building the world's leading biotech ecosystem but we're now operating in a very different environment," ABIA founder Patroski Lawson said in the release. Organizers say they plan to bring together leaders from industry, investment and academia and turn those worries into a concrete playbook.
What The Alliance Says
According to ABIA, the group frames the challenge with blunt numbers. U.S. firms still account for roughly 55% of global biopharma R&D investment, but China holds an outsized share of active pharmaceutical ingredient production, and U.S. companies offshore a significant share of drug-development workflows. ABIA argues that these dependencies create economic and health-security risks that need a coordinated response. The group lays out a "Vision 2030" roadmap centered on workforce, manufacturing muscle and modernized regulation.
Massachusetts' Pipeline And The Pressure
Massachusetts is hardly slacking on discovery. The state's drug-candidate pipeline grew nearly 14% in 2025, compared with a 6.8% national increase and roughly 37% growth in China, according to MassBio. Industry leaders point to that gap as one reason they want more manufacturing and scale-up capacity at home rather than relying on partners half a world away. MassBio also notes that Massachusetts companies have secured dozens of FDA approvals and punch above their weight in U.S. innovation. Advocates warn that without targeted policy and capital, many of those scientific wins could be commercialized elsewhere.
Local Members Behind The Push
Citing local filings and company disclosures, Axios lists Cambridge-based Moderna and Boston-based Praxis among ABIA's founding members and notes that the roster also includes smaller regional outfits such as Milestone Heights. Some names on the list are multinationals. Pharvaris reports U.S. office leases in Lexington in its regulatory filings, and Prilenia identifies Waltham as its U.S. hub in company announcements. Backers say pairing big-platform companies with scrappier local innovators is meant to better connect discovery, clinical trials and scale-up across the state.
Supply-Chain And Policy Stakes
A 2025 analysis from RAND found that U.S. biopharma firms outsource roughly 30% of FDA-approved drug workflows to Chinese contract development and manufacturing organizations and warned that replacing that capacity could take years. That reliance is a central talking point for ABIA supporters, who argue that federal incentives, targeted manufacturing investments and streamlined regulation are needed to rebuild resilience. Critics of aggressive decoupling counter that moving too fast could snarl drug supplies and disrupt the collaborations many companies depend on right now.
What ABIA Plans Next
Next up for the alliance is recruiting a "Founding Fifty" and staging regional convenings to shape a national strategy, according to ABIA. The goal is a practical blueprint for policymakers, investors and industry leaders that spells out where the U.S. should double down on manufacturing, workforce and R&D hubs. ABIA casts its work as complementary to existing trade groups, with a focus on long-range alignment rather than the daily skirmishes of lobbying.
For Massachusetts, the effort signals that local companies want federal policy and capital to keep pace with the state's fast-growing pipeline. Turning lab breakthroughs into domestic manufacturing and high-value jobs will require sustained federal investment and targeted incentives, MassBio leaders argue, according to MassBio.
